JohnPLeonardMD

PubMed

• Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research Agenda.
  Bryan Valcarcel, Kerry J Savage, Brian K Link, John P Leonard, Kara M Kelly
  JCO Oncology Practice. 2024-12-06
• 2 citations
  Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
  Mitchell R Smith, Opeyemi A Jegede, Peter Martin, Brian G Till, Samir S Parekh
  Blood. 2024-09-05
• Racial Disparities in Endometrial Cancer Clinical Trial Representation: Exploring the Role of Eligibility Criteria.
  Jennifer L Wolf, Alexandra Hamilton, Anjile An, John P Leonard, Margaux J Kanis
  American Journal of Clinical Oncology. 2024-08-01

Journal Articles

• Five-Year Follow-up of Lenalidomide plus Rituximab as Initial Treatment for Mantle Cell Lymphoma  
  Jia Ruan, Jakub Svoboda, John P Leonard, Sonali M Smith, Morton Coleman, Richard R Furman, Blood
• CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PET  
  David J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood

Abstracts/Posters

• Consensus and Divergence in Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Patients with Mantle Cell Lymphoma
  John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Subgroup Analyses of Elderly Patients Aged _ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo...
  John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of...
  John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study
  John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001
  John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies
  John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ...
  John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma
  John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Continuing Medical Education and Patient Education on Follicular Lymphoma: Changes in Clinician Practice, Patient Behaviors, and Knowledge across Clinicians and Patients
  John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling
  John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival i...
  John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)
  John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as...
  John P. Leonard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Hodgkin Lymphoma: Genes to Microenvironment to Immunotherapy 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Follicular Lymphoma: Have We Made Progress? 
  60th American Society of Hematology Annual Meeting - 12/3/2018
• The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all